Gene Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene Symbol FLT3
Synonyms CD135 | FLK-2 | FLK2 | STK1
Gene Description FLT3, fms related receptor tyrosine kinase 3, activates Akt, Ras, and Erk pathways to regulate differentiation, proliferation, and survival of hematopoietic progenitor cells (PMID: 29316714, PMID: 28538663). Activating mutations of FLT3 are common in hematologic tumors (PMID: 19467916) and the internal tandem duplication (ITD) mutation is commonly observed in acute myeloid leukemia (PMID: 30181385, PMID: 32241850).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06235801 Phase Ib/II Gilteritinib + Momelotinib A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Not yet recruiting USA 0
NCT05546580 Phase I Gilteritinib + ORY-1001 Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (FRIDA) Recruiting USA 0
NCT04140487 Phase Ib/II Azacitidine + Gilteritinib + Venetoclax Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm Active, not recruiting USA 0
NCT02752035 Phase II Gilteritinib Azacitidine + Gilteritinib Azacitidine A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT04655391 Phase I Glasdegib Glasdegib + Ivosidenib Bosutinib + Glasdegib Gilteritinib + Glasdegib Decitabine + Glasdegib + Venetoclax Enasidenib + Glasdegib Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation Withdrawn USA 0
NCT02400255 Phase II Crenolanib Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients Completed USA 0
NCT03250338 Phase III Cytarabine + Filgrastim + Fludarabine + Idarubicin + Mitoxantrone Crenolanib + Cytarabine + Filgrastim + Fludarabine + Idarubicin + Mitoxantrone Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML Recruiting USA | ITA | FRA | ESP | DEU | CAN 0
NCT06022003 Phase II Azacitidine + Gilteritinib Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects >=18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (OGILAR) Recruiting FRA 0
NCT05520567 Phase Ib/II Azacitidine + Gilteritinib + Venetoclax A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia Recruiting USA 0
NCT05010122 Phase Ib/II Decitabine and Cedazuridine + Gilteritinib + Venetoclax ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT03512197 Phase III Daunorubicin + Midostaurin Cytarabine + Idarubicin + Midostaurin Cytarabine + Idarubicin Daunorubicin A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) Completed USA | ITA | FRA | ESP | DEU | BEL | AUT | AUS 12
NCT02335814 Phase I FLX925 First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia Terminated USA 0
NCT03922100 Phase Ib/II NMS-P088 Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML Recruiting ITA | FRA | ESP 0
NCT05697510 Phase I Siltuximab Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM (SILTUXILAM) Recruiting FRA 0
NCT05558124 Phase I CPX-351 + Gemtuzumab ozogamicin CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML Recruiting USA 0
NCT05886049 Phase I Cytarabine + Daunorubicin + Revumenib Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene Recruiting USA 0
NCT06152809 Phase I Aldesleukin + CIML-NK cells + Venetoclax CIML NK Cells With Venetoclax for AML Active, not recruiting USA 0
NCT05330377 Phase I Cladribine + Cytarabine + Filgrastim + Gilteritinib + Mitoxantrone GM-CLAG in Relapsed/Refractory FLT3-mutated AML Withdrawn USA 0
NCT04817241 Phase Ib/II Cytarabine + Daunorubicin Decitabine and Cedazuridine + Venetoclax Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients Active, not recruiting USA 0
NCT04027309 Phase III Midostaurin Gilteritinib A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML) Active, not recruiting NLD | FRA | ESP | DEU | BEL | AUT | AUS 7
NCT05756777 Phase I Gilteritinib + Ivosidenib Enasidenib + Gilteritinib A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) Recruiting USA 0
NCT04669067 Phase Ib/II KRT-232 + TL-895 TL-895 and KRT-232 Study in Acute Myeloid Leukemia Active, not recruiting USA | ITA | FRA | ESP | DEU | AUT | AUS 1
NCT04168502 Phase III Gemtuzumab ozogamicin + Glasdegib Gemtuzumab ozogamicin Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML Recruiting ITA 0
NCT05024552 Phase I CPX-351 + Gilteritinib Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML Recruiting USA 0
NCT06222580 Phase I Gilteritinib + Revumenib SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation Recruiting USA 0
NCT04385290 Phase Ib/II Cytarabine + Daunorubicin + Gemtuzumab ozogamicin + Midostaurin Cytarabine + Daunorubicin + Gemtuzumab ozogamicin Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) (MOSAIC) Recruiting DEU 0
NCT01892371 Phase Ib/II Azacitidine + Quizartinib Cytarabine + Quizartinib Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT02356159 Phase Ib/II Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate Cyclophosphamide + Fludarabine Rituximab Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Recruiting USA 0
NCT04616248 Phase I CDX-1140 + CDX-301 + Poly ICLC In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors Recruiting USA 0
NCT03934372 Phase Ib/II Ponatinib Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Recruiting NLD | ITA | GBR | FRA | ESP | DEU | BEL 2
NCT02381548 Phase I Adavosertib + Belinostat Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia Terminated USA 0
NCT04214249 Phase II Cytarabine + Daunorubicin Cytarabine Cytarabine + Idarubicin Pembrolizumab Cytarabine + Daunorubicin + Pembrolizumab Cytarabine + Pembrolizumab Cytarabine + Idarubicin + Pembrolizumab BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia Recruiting USA 0
NCT02323607 Phase I Cytarabine + Daunorubicin + Pacritinib Decitabine + Pacritinib Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations Completed USA 0
NCT02315625 Phase II Everolimus Sunitinib Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery Terminated USA 0
NCT04051996 Phase II Decitabine + Glasdegib GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia Terminated USA 0
NCT02418000 Phase Ib/II E6201 A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation Terminated USA 0
NCT02530476 Phase Ib/II Selinexor + Sorafenib Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia Completed USA 0
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy in CBT Recruiting USA 0
NCT03836209 Phase II Cytarabine + Daunorubicin + Gilteritinib Cytarabine + Daunorubicin + Midostaurin Cytarabine Midostaurin Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03620318 Expanded access Crenolanib Individual Patient Compassionate Use of Crenolanib Available ITA 0
NCT04491084 Phase Ib/II CDX-1140 + CDX-301 FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy (FLT3) Terminated USA 0
NCT05010200 Phase I CDX-301 + PGV 001 + Poly ICLC PGV 001 + Poly ICLC The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting. (PGV-Prostate) Recruiting USA 0
NCT02723435 Phase II Midostaurin Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant Withdrawn 0
NCT01338987 Phase II Tacrolimus Busulfan Methotrexate Leuprolide Cyclophosphamide Fludarabine Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation Completed USA 0
NCT02543879 Phase I FT-1101 Azacitidine + FT-1101 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Completed USA 0
NCT05918692 Phase I BMF-500 A Phase 1, Study of BMF-500 in Adults With Acute Leukemia Recruiting USA 0
NCT03913026 Phase II ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia Active, not recruiting CAN 0
NCT03625505 Phase I Gilteritinib + Venetoclax A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia Completed USA 0
NCT04409639 Phase II Cobimetinib Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (CONCERTO) Recruiting USA 0
NCT00887068 Phase III Azacitidine Randomized Allogeneic Azacitidine Study Completed USA 0
NCT04659616 Phase I Cytarabine + Pemigatinib Cytarabine + Daunorubicin + Pemigatinib Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia Recruiting USA 0
NCT05279859 Phase Ib/II ERAS-007 + Gilteritinib A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies (HERKULES-4) Withdrawn USA 0
NCT04801797 Phase II Azacitidine + Venetoclax Cytarabine + Idarubicin Cytarabine + Daunoxome Cytarabine + Daunorubicin Venetoclax + Azacitidine vs. Induction Chemotherapy in AML Recruiting USA 0
NCT04223596 Phase II Brigatinib Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (CUBIK) Active, not recruiting ESP 0
NCT02624570 Phase I Midostaurin Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy. No longer available USA 0
NCT03297606 Phase II Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) Recruiting CAN 0
NCT03194685 Phase Ib/II FF-10101 Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed USA 0
NCT02126553 Phase II Lenalidomide Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission Completed USA 0
NCT02756962 Phase II Midostaurin Cytarabine Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance Active, not recruiting USA 0
NCT03709758 Phase I Cytarabine + Daunorubicin + Venetoclax Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naive AML Recruiting USA 0
NCT06001788 Phase I Gilteritinib + Ziftomenib Cytarabine + Ziftomenib Cytarabine + Filgrastim + Fludarabine + Idarubicin + Ziftomenib Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia Recruiting USA 0
NCT02693535 Phase II Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) Recruiting USA 0
NCT05028751 Phase Ib/II Gilteritinib + Lanraplenib A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) Terminated USA | ESP 0
NCT03591510 Phase II Cytarabine Cytarabine + Etoposide Cytarabine + Mitoxantrone Cytarabine + Fludarabine + Idarubicin Cytarabine + Daunorubicin + Fludarabine Cytarabine + Daunoxome + Fludarabine Midostaurin A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML Recruiting USA | ITA | DEU | AUT 9
NCT02400281 Phase Ib/II Azacitidine Crenolanib Cytarabine + Idarubicin Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients Completed USA 0
NCT03730012 Phase Ib/II Atezolizumab + Gilteritinib A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) Completed USA 0
NCT02634827 Phase II Decitabine + Midostaurin Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation Terminated USA 0
NCT01883362 Phase II Midostaurin Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Completed USA | CAN 0
NCT02487459 Phase I Rivogenlecleucel Rimiducid Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies Withdrawn USA 0
NCT04988555 Phase Ib/II DSP-5336 A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation Recruiting USA 1
NCT03070093 Expanded access Gilteritinib Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) Approved for marketing USA | CAN 1
NCT04536077 Phase II CDX-1140 + CDX-301 CDX-1140 Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients Terminated USA 0
NCT01831726 Phase II Dovitinib Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Completed USA 0
NCT02747537 Phase II Irinotecan + Sorafenib Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan Withdrawn 0
NCT02270788 Phase I Cytarabine + Leucovorin + Methotrexate Crenolanib + Sorafenib Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies Completed USA 0
NCT02193152 Phase I Pazopanib Pazopanib in Molecularly Selected Patients With Advanced NSCLC Terminated USA 0
NCT02829840 Phase Ib/II Azacitidine + Ponatinib Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) Withdrawn 0
NCT03114228 Expanded access Midostaurin An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) No longer available CAN 0
NCT04982354 Phase Ib/II Busulfan + CPX-351 + Fludarabine + Melphalan + Midostaurin Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia Recruiting USA 0
NCT03825796 Phase II CPX-351 + Enasidenib Cytarabine + Enasidenib Enasidenib CPX-351 Plus Enasidenib for Relapsed AML Active, not recruiting USA 0
NCT03613532 Phase I Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Recruiting USA 0
NCT02532231 Phase II Nivolumab Nivolumab in AML in Remission at High Risk for Relapse Completed USA 0
NCT03701295 Phase Ib/II Azacitidine + Pinometostat Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement Completed USA 0
NCT04631744 Phase II Cabozantinib Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Recruiting USA 0
NCT02925234 Phase II Palbociclib Ribociclib Lenvatinib Ipilimumab + Nivolumab Trametinib Crizotinib Niraparib Selpercatinib Olaparib Erlotinib Erdafitinib Dabrafenib Dacomitinib Rucaparib Axitinib Panitumumab Pemigatinib Durvalumab Afatinib Entrectinib Tepotinib Alpelisib Atezolizumab + Bevacizumab Alectinib Regorafenib Cobimetinib + Vemurafenib Nilotinib Vismodegib Abemaciclib Sunitinib Nivolumab Cabozantinib Lorlatinib Talazoparib Dabrafenib + Trametinib Pembrolizumab Pertuzumab + Trastuzumab The Drug Rediscovery Protocol (DRUP Trial) (DRUP) Recruiting NLD 0
NCT05904106 Phase II Cytarabine Azacitidine + Venetoclax Cytarabine + Daunorubicin + Gemtuzumab ozogamicin Cytarabine + Mitoxantrone Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML (VINCENT) Not yet recruiting DEU 0
NCT02421939 Phase III Cytarabine Cytarabine + Fludarabine + Idarubicin Cytarabine + Etoposide + Mitoxantrone Azacitidine Gilteritinib Filgrastim A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 6
NCT02272998 Phase II Ponatinib Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. Active, not recruiting USA 0
NCT01657682 Phase II Crenolanib A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations Completed USA 0
NCT03900949 Phase I Midostaurin Cytarabine Cytarabine + Gemtuzumab ozogamicin Cytarabine + Daunorubicin + Gemtuzumab ozogamicin Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia Recruiting USA 0
NCT02283177 Phase II Crenolanib + Cytarabine + Daunorubicin A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations Completed USA 0
NCT03701308 Phase II Cytarabine + Daunorubicin Cytarabine + Uproleselan Cytarabine + Daunorubicin + Uproleselan Cytarabine Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy Suspended USA 0
NCT05658640 Phase Ib/II Cyclophosphamide + Cytarabine + Dexamethasone + Trametinib HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (HEM-iSMART D) Not yet recruiting NLD 0
NCT04116541 Phase II Alectinib Cabozantinib Ribociclib + Siremadlin A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) Recruiting FRA 0
NCT03674411 Phase II Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Active, not recruiting USA 0
NCT03513484 Phase I Azacitidine + Nintedanib Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04518345 Phase Ib/II Dubermatinib Azacitidine + Dubermatinib TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia Completed USA 0
NCT05183035 Phase III Azacitidine + Cytarabine + Fludarabine + Gemtuzumab ozogamicin + Venetoclax Azacitidine + Cytarabine + Fludarabine + Gemtuzumab ozogamicin Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) Recruiting USA | NZL | NLD | ITA | FRA | ESP | CAN | BEL | AUT | AUS 7
NCT04872478 Phase I MRX-2843 Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL Recruiting USA 0
NCT04107727 Phase II Cytarabine Cytarabine + Idarubicin Cytarabine + Idarubicin + Quizartinib Quizartinib Cytarabine + Quizartinib Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Active, not recruiting ESP 0
NCT04493138 Phase Ib/II Azacitidine + Quizartinib Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations Recruiting USA 0
NCT04240002 Phase Ib/II Cytarabine + Filgrastim + Fludarabine + Gilteritinib A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 0
NCT02270463 Phase Ib/II Tagraxofusp-erzs SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission Terminated USA 0
NCT02927262 Phase III Gilteritinib A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission Completed USA | ITA | GBR | FRA | ESP | DEU | CAN 14
NCT03661307 Phase Ib/II Decitabine + Quizartinib + Venetoclax Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04209725 Phase II CPX-351 + Quizartinib A Study of CPX-351 (Vyxeos) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia Terminated USA 0
NCT03690115 Phase II Ponatinib Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients (PONALLO) Active, not recruiting FRA 0
NCT04336982 Phase Ib/II Azacitidine + CC-90009 + Venetoclax CC-90009 + Gilteritinib A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia Active, not recruiting USA | GBR | FRA | CAN | BEL 0
NCT03735875 Phase Ib/II Quizartinib + Venetoclax Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia Completed USA 0
NCT03793478 Phase Ib/II Etoposide Cytarabine + Fludarabine + Methotrexate + Prednisolone + Quizartinib Cytarabine + Daunorubicin + Fludarabine + Methotrexate + Prednisolone + Quizartinib Cytarabine + Daunorubicin + Fludarabine + Hydrocortisone + Methotrexate + Quizartinib Cytarabine + Fludarabine + Methotrexate + Prednisolone Quizartinib Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood Recruiting USA | NLD | ITA | GBR | FRA | ESP | CAN | BEL 3
NCT03552029 Phase I Milademetan + Quizartinib Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) Terminated USA 0
NCT03365661 Phase II Nogapendekin alfa inbakicept QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML Withdrawn USA 0
NCT02997202 Phase III Gilteritinib A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) Completed USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 6
NCT02039726 Phase III Cytarabine + Fludarabine Cytarabine + Etoposide + Mitoxantrone Quizartinib Filgrastim + Idarubicin (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 9
NCT02668653 Phase III Cytarabine + Daunorubicin + Idarubicin Cytarabine + Daunorubicin + Idarubicin + Quizartinib Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 19
NCT01266083 Phase II WT1 vaccine Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Completed USA 0
NCT01398462 Phase I CWP232291 Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients Completed USA 1
NCT02846376 Phase I Ipilimumab Ipilimumab + Nivolumab Nivolumab Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) Terminated USA 0
NCT03904069 Phase I Anti-FLT3 CAR-T cells Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML Withdrawn USA 0